Abstract
Earlier this year our dear friend and colleague Professor Tony Dodi died suddenly. He was a Scientist of immense integrity and worked with many of the authors who have contributed to the current series of articles focussing on Cancer Biomarkers. His laboratory at Nottingham Trent University (NTU) authored the article entitled “NK Cells, monocytes and Non T-cell biomarkers as prognostic indicators in cancer immunotherapy” in issue 1 and he contributed enormously to the progress and wellbeing of the ENACT Research programme funded by the EU under FP6. During his career, Tony worked with Robert Lachler and Richard Bachelor at The Royal Postgraduate Medical School, Hammersmith London, prior to joining Professor Alejandro Madrigal at the Anthony Nolan Research Institute. In 2005, Tony was appointed as Professor of Haemato-oncology and Head of Leukaemia Research at NTU. He also continued to head the Immunotherapy Group at the Anthony Nolan Research Institute in London. His legacy exists in the research he undertook in the field of Cancer Immunotherapy and Transplantation Immunology and he was recently involved in the development of the Anthony Nolan Cord Blood Programme, which was developed as a result of his enthusiasm and energy. From the outset, I admired his research ability and determination and consider it to be a distinct privilege as well as pleasure to have known Tony as a colleague and close friend. He is sorely missed by all who knew him and we wish to dedicate this series of papers to his memory. We will not forget Tonys contribution to our research endeavours.
Current Cancer Therapy Reviews
Title: Dedication to Professor Tony Dodi
Volume: 4 Issue: 2
Abstract: Earlier this year our dear friend and colleague Professor Tony Dodi died suddenly. He was a Scientist of immense integrity and worked with many of the authors who have contributed to the current series of articles focussing on Cancer Biomarkers. His laboratory at Nottingham Trent University (NTU) authored the article entitled “NK Cells, monocytes and Non T-cell biomarkers as prognostic indicators in cancer immunotherapy” in issue 1 and he contributed enormously to the progress and wellbeing of the ENACT Research programme funded by the EU under FP6. During his career, Tony worked with Robert Lachler and Richard Bachelor at The Royal Postgraduate Medical School, Hammersmith London, prior to joining Professor Alejandro Madrigal at the Anthony Nolan Research Institute. In 2005, Tony was appointed as Professor of Haemato-oncology and Head of Leukaemia Research at NTU. He also continued to head the Immunotherapy Group at the Anthony Nolan Research Institute in London. His legacy exists in the research he undertook in the field of Cancer Immunotherapy and Transplantation Immunology and he was recently involved in the development of the Anthony Nolan Cord Blood Programme, which was developed as a result of his enthusiasm and energy. From the outset, I admired his research ability and determination and consider it to be a distinct privilege as well as pleasure to have known Tony as a colleague and close friend. He is sorely missed by all who knew him and we wish to dedicate this series of papers to his memory. We will not forget Tonys contribution to our research endeavours.
Export Options
About this article
Cite this article as:
Dedication to Professor Tony Dodi, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310106
DOI https://dx.doi.org/10.2174/157339408784310106 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry Trp/Met/Phe Hot Spots in Protein-Protein Interactions: Potential Targets in Drug Design
Current Topics in Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Cytotoxic Activity of Polysubstituted 7-chloro-4-quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Atomic Force Microscopy: The Characterisation of Amyloid Protein Structure in Pathology
Current Topics in Medicinal Chemistry Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Biology of Protooncogene c-kit Receptor and Spermatogenesis
Current Pharmacogenomics Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets The Role of Soluble 5'-Nucleotidases in the Conversion of Nucleotide Analogs: Metabolic and Therapeutic Aspects
Current Medicinal Chemistry Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies An Overview on 2-arylquinolin-4(1H)-ones and Related Structures as Tubulin Polymerisation Inhibitors
Current Topics in Medicinal Chemistry